Decoy Therapeutics Inc. (DCOY)vsBeiGene, Ltd. (ONC)
DCOY
Decoy Therapeutics Inc.
$3.58
+1.42%
HEALTHCARE · Cap: $2.16M
ONC
BeiGene, Ltd.
$347.48
-2.40%
HEALTHCARE · Cap: $40.64B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 10.7% profit margin vs 0.0%. DCOY trades at a lower P/E of 0.0x. ONC earns a higher WallStSmart Score of 54/100 (C-).
DCOY
Avoid26
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCOY.
Margin of Safety
+80.3%
Fair Value
$1785.72
Current Price
$347.48
$1438.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DCOY
The strongest argument for DCOY centers on P/E Ratio, Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.
Bear Case : DCOY
The primary concerns for DCOY are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.2x leaves little room for execution misses.
Key Dynamics to Monitor
DCOY profiles as a value stock while ONC is a growth play — different risk/reward profiles.
DCOY carries more volatility with a beta of 0.58 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 26/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Decoy Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?